Search
hydromethylthionine mesylate; leucomethylene blue dimesylate (HMTM)
Indications:
- experimental oral agent for prevention of Alzheimer's disease in elderly with mild cognitive impairment
* improves cognition over 18 months in elderly with mild cognitive impairment
Dosage:
- 16 mg PO QD
Adverse effects:
- urine discoloration
Mechanism of action:
- experimental oral tau aggregation inhibitor
- struturally related to methylene blue
- 93% reduction of plasma neurofilament light chain over 12 months
- attenuates increase in plasma ptau181
Related
methylene blue; methylthioninium chloride (Provablue, MTC)
General
pigment
tau aggregation inhibitor
Database Correlations
PUBCHEM cid=60150609
References
- Brooks M
Oral Tau Inhibitor Continues to Show Promise in Alzheimer's
Medscape. July 21, 2023
https://www.medscape.com/viewarticle/994646